CBD Affects Your Body's Own Cannabis Molecules—But Differently in Men and Women

Triple-blind, placebo-controlled, randomized crossover trial. 70 healthy occasional cannabis users received 10 sequences of 4 oral CBD doses (20, 50, 100, 200 mg) and placebo. Blood sampled at baseline and 5 post-dose timepoints. Plasma AEA, PEA, and OEA quantified by LC-MS. Linear mixed-effects models with participant ID nested in sequence as random effect, including sex as a variable.

Most people taking CBD products have no idea whether or how it's affecting their endocannabinoid system. This study shows that even the lowest commercially available dose (20 mg) has measurable effects on endocannabinoid signaling—and that biological sex modifies those effects. For a product marketed as one-size-fits-all, the sex difference finding suggests dosing may need to be personalized.

The sex difference finding parallels RTHC-00155's discovery that cannabis + alcohol impaired memory in men but not women. RTHC-00220 showed that 86% of cannabis users have atypical metabolizing enzyme variants—this study adds biological sex as another source of variability. Together, they paint a picture of cannabis response that's far more individual than the product labels suggest. The anandamide modulation also connects to RTHC-00005's foundational discovery of anandamide itself.

Occasional cannabis users—results may differ in naive or chronic users. Plasma levels of endocannabinoids may not reflect brain or tissue levels. The study measured acute effects; chronic CBD use might produce different patterns. Marketed CBD products vary in actual content, so the controlled doses here may not match real-world products. The 2026 publication date means this is very recent and awaits replication.